Artbio raises 90m USD

Artbio, which is based in Cambridge, Massachusetts, and maintains a presence in Basel (Switzerland), has raised a total of 90 million US dollars as part of an oversubscribed and upsized Series A financing round, further details of which can be found in a press release. Artbio is developing a new class of alpha radioligand therapies (ART). This enables targeted therapy in which tumor-specific target structures are selected. Artbio’s lead program is intended to treat prostate cancer, with the fresh capital set to be used to advance this research.

Moreover, the AlphaDirect technology from Artbio facilitates decentralized manufacturing. A corresponding production network is also set to be further developed on the back of the success of the financing round.